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Major Depressive Disorders (MDD) patients may exhibit cognitive deficits and it
is currently unclear to which degree treatment with antidepressants may affect
cognitive function. Preclinical and clinical observations showed that vortioxetine (VORT,
an antidepressant with multimodal activity), presents beneficial effects on aspects
of cognitive function. In addition, VORT treatment increases adult hippocampal
neurogenesis (AHN) in rodents, a candidate mechanism for antidepressant activity.
Pattern separation (PS) is the ability to discriminate between two similar contexts/events
generating two distinct and non-overlapping representations. Impaired PS may lead
to overgeneralization and anxiety disorders. If PS impairments were described
in depressed patients, the consequences of antidepressant treatment on context
discrimination (CD) are still in its infancy. We hypothesized that VORT-increased
AHN may improve CD. Thus, in an attempt to elucidate the molecular mechanism
underpinning VORT treatment effects on CD, a rodent model of PS, the role of AHN
and stress-induced c-Fos activation was evaluated in the adult mouse hippocampus.
Chronic treatment with VORT (1.8 g/kg of food weight; corresponding to a daily dose
of 10 mg/kg, 3 weeks) improved CD in mice. Interestingly, chronic treatment with
VORT reversed ablation of AHN-induced delay in CD and freezing behavior. VORT
treatment decreased stress-induced c-Fos activation in the dorsal but not ventral
dentate gyrus. VORT treatment did not affect c-Fos activity in the hippocampus of mice
with ablated neurogenesis. This study highlights a role of VORT in CD, which may be
independent from AHN and hippocampal c-Fos activation. Further studies elucidating
the mechanisms underlying VORT’s effects in CD could contribute to future strategies
for alleviating the disease burden for individuals suffering from depression and/or anxiety
disorders.
Keywords: vortioxetine, context discrimination, neurogenesis, c-Fos, mice

INTRODUCTION
Major depressive disorders (MDD) and anxiety disorders are common health problems in today’s
society and display high comorbidity although the pathologies differ. MDD patients may also
exhibit cognitive dysfunction in various domains, e.g., memory (verbal and visual), learning and
attention (Austin et al., 2001; Darcet et al., 2016). MDD may be associated with impairments in
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pattern separation (PS), a mechanism for encoding very similar
memories in non-overlapping and distinct representations.
Impairments in PS may lead to overgeneralization of memory,
which may contribute to the development of disorders such
as post-traumatic stress and panic disorder (Kheirbek et al.,
2012). Preclinical evidence suggests that adult hippocampal
neurogenesis (AHN) plays a role in context discrimination
(CD), a rodent model of PS and that increased AHN
improves CD in mice (Sahay et al., 2011a; Guilloux et al.,
2017).
It is currently unclear how treatment with antidepressants
may affect cognitive functions (Fava, 2003). Although many
studies found that a wide range of antidepressant treatments were
able to improve both mood and cognitive-related symptoms in
MDD (for review Darcet et al., 2016) others failed to show an
association between antidepressant treatment and improvement
in cognitive functions in depressed patients (Marcourakis
et al., 1993; Knegtering et al., 1994; Amado-Boccara et al.,
1995; Stein and Strickland, 1998; de Carvalho et al., 2002;
Gorenstein et al., 2006; Frampton, 2016). About 50–60% of
MDD patients have recurrent episodes (Darcet et al., 2016). This
group of MDD patients is the one most affected by cognitive
symptoms.
Vortioxetine (VORT) is an antidepressant with multimodalactivity (Tritschler et al., 2014), which combines serotonin
(5-HT) transporter inhibition with actions at 5-HT receptors
(agonist at 5-HT1A ; partial agonist at 5-HT1B ; antagonist at
5-HT1D , 5-HT3 , and 5-HT7 receptors) (Sanchez et al., 2015).
Recent clinical and preclinical data suggest that treatment with
VORT has beneficial effect on aspects of cognitive function
(Al-Sukhni et al., 2015; Mahableshwarkar et al., 2015; Sanchez
et al., 2015; McIntyre et al., 2016). Specifically, preclinical data
demonstrate that VORT improves memory in rats through 5HT receptor-dependent mechanisms (Mork et al., 2013; du Jardin
et al., 2014; Jensen et al., 2014; Betry et al., 2015; Westrich et al.,
2015). Similarly, clinical trials suggest that VORT does not affect
cognitive functions negatively in healthy subjects (Theunissen
et al., 2013) and displays some beneficial effects on cognition
in adults and elderly depressed patients (Katona et al., 2012;
McIntyre et al., 2014; Mahableshwarkar et al., 2015, 2016; Smith
et al., 2017). In addition, chronic treatment with VORT has
been shown to increase AHN in 129SvEV mice (Guilloux et al.,
2013).
Recent studies have implicated adult-born hippocampal
neurons in CD, a process by which similar experiences or events
are transformed into discrete, non-overlapping representations
(Treves et al., 2008). Cognitive deficits consistent with impaired
CD in MDD patients have been also described (Shelton and
Kirwan, 2013). Actually, depressed individuals have lower PS
abilities than non-depressed individuals. We hypothesized that
VORT-increased AHN (Guilloux et al., 2013) may improve CD.
Thus, this study aimed to investigate whether chronic
treatment with VORT improved CD in mice. Then, in order
to gain further insights in the CD processes targeted by VORT,
we investigated whether AHN affects CD response in VORTtreated animals and if hippocampal neuronal activity changes
were observed.
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MATERIALS AND METHODS
Animals
Vortioxetine and Context Discrimination
C57BL/6J Rj male mice, 2 months old (Janvier Labs, France) were
used to assess CD (see timeline, Figure 1).

Role of Adult Hippocampal Neurogenesis in
Vortioxetine-Increased Context Discrimination
GFAP-TK+ mouse model
In order to assess the role of AHN on CD, glial fibrillary acidic
protein (GFAP)-Thymidine kinase (TK+ ) male mice were used.
Mice were generated as previously described (Mendez-David
et al., 2017). An agreement (license L-O 15-2015/0) between the
NIH and the Université Paris-Sud provides CESP/UMRS 1178
laboratory with the use of transgenic mice that express herpes
simplex virus (HSV) TK under control of the GFAP promoter
(GFAP-TK mice), as previously described (Snyder et al., 2011;
Mendez-David et al., 2017) and developed in the laboratory of
Dr. Heather Cameron of the National Institute of Mental Health
(NIMH).
Mice were maintained under standard conditions (12/12h
light/dark cycle, lights on at 6 AM, 22 ± 1◦ C, food and water ad
libitum, five mice per cage). All behavioral testing was performed
during the light cycle from 9:00 to 15:00. The protocols
involving animals and their care were conducted in conformity
with the institutional guidelines that are in compliance with
national and international laws and policies (Council directive
# 87-848, October 19, 1987, Ministére de l’Agriculture et de
la Forêt, Service Vétérinaire de la Santé et de la Protection
Animale, permissions # 92-256B to DD and with the European
Communities Council Directive 2010/63/UE) and in compliance
with protocols approved by the Institutional Animal Care and
Use Committee (CEE26 authorization 2012-099).

Drug Treatment
Vortioxetine (VORT) Treatment
Vortioxetine HBr was incorporated into Purina 5001 rodent
chow at a concentration of 1.8 g/kg of food weight (Research
Diets, Inc., New Brunswick, NJ, United States). This dose results
in engagement of all VORT’s primary pharmacological targets.
VORT (1.8 g/kg of food weight; ∼10 mg/kg) was administered
for 3 weeks’ in C57BL/6J Rj and 4 weeks’ in GFAP-TK+ mice
study prior the start of the CD protocol (Figure 1). Chronic
treatment with VORT has been shown to not affect body weight
(Supplementary Figure S1).

Ganciclovir Administration
Ganciclovir [Rodent Diet, Grain-Based, Valganciclovir (VGCV,
Roche, Indianapolis, IN, United states) 165 mg/kg; Custom
Animal Diets, LLC] was administered in the chow for 4 weeks
prior the start of CD protocol using the method reported in
previous studies (Saxe et al., 2006, 2007; Lugert et al., 2017). GCV
treatment continued until the end of the study. GCV was weekly
removed on Friday, Saturday, and Sunday as described in Lugert
et al. (2017) and Mendez-David et al. (2017). GFAP-TK-positive
(GFAP-TK+ ) mice received regular chow (NON-GCV) or VGCV,
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FIGURE 1 | Experimental protocol.

of 0.4 mA, 185 s following placement in the chamber. Mice
were taken out of the chamber 15 s following termination of
the foot shock and returned to their home cage. Three hours
later, mice were placed in the similar context in which they
were left for 180 s and were never shocked. In this study
context A (shock-paired) and context B (shock-unpaired) was
presented randomly for 8 days, except on day zero in which
mice were exposed to context A alone (Figure 1). From day
9 of PS, context A was always followed by context B until
the end of the test. Measurement of freezing levels in both
training context (3 min pre-shock) and in the similar context
(3 min) each day allowed assessment of discrimination between
the two contexts and was computed as a Discrimination ratio:
(Freezing Training context − Freezing similar context)/(Freezing
Training context + Freezing similar context). A score of 0
indicates complete lack of discrimination, i.e., freezing levels
are the same in the similar and training contexts (Freezing
similar context = Freezing Training context), whereas a score
of 1 indicates perfect discrimination, i.e., freezing-level in the
similar context is zero (Freezing similar context = 0). Behavior
was recorded by a digital video camera and freezing behavior

the L-valyl ester of ganciclovir, has a high (approximately 85%)
bioavailability and is rapidly converted into ganciclovir by
intestinal and hepatic esterases after oral administration. After
phosphorylation by HSV-TK ganciclovir is toxic to proliferating
cells in S-phase of mitosis.

Behavioral Analysis
Context Discrimination (CD)
This paradigm tests the animals’ ability to distinguish between
two similar contexts, conditions that are most likely to recruit
the dentate gyrus (DG) (Sahay et al., 2011a). Testing was
conducted in chambers (25 cm × 25 cm × 25 cm) with
3 methacrylate walls, 1 aluminum wall, and a stainless steel
grid floor, which is encased in a sound attenuating box [67
(W) cm × 53 (D) cm × 55 (H) cm]. The shock associated
training context A and the similar (no-shock) context B were
characterized by similar features (stainless grid floor, cube box)
and non-similar features (context A: rectangular box shape, light
on, anise scent; context B: round box shape, light off, lemon
scent). For discrimination learning, mice were exposed to the
training context in which they received a single 2 s foot shock

Frontiers in Pharmacology | www.frontiersin.org

3

March 2018 | Volume 9 | Article 204

Felice et al.

Vortioxetine Improves Context Discrimination in Mice

United States). Statistical outliers were removed from the analysis
[outlier = average ± (2∗ SD); Experiment 2: GCV VEH: 2 outliers;
VORT: 1 outlier; GCV VORT: 3 outliers]. Figure 4C, outliers:
1 outlier in VORT group (Figure 4C); 2 outliers in VEH group
and 3 outliers in VORT group (Figure 4D). DCX analysis,
Supplementary Figure S2: 2 outliers in VEH group and 1 outlier
in VORT group.

was analyzed with Freezing Software version 2.0.04 (Packwin,
Harvard apparatus, Bioseb, France).

c-Fos Immunohistochemistry
Two hours following foot shock stress in context A (Figure 1),
deeply anesthetized animals (100 mg/ml ketamine; 20 mg/ml
xylazine) were perfused transcardially with phosphate buffer
solution (PBS) followed by cold paraformaldehyde (PFA, 4% w/v
in PBS). Brains were removed and kept in 4% PFA overnight at
4◦ C. After the post-fixation period, brains were cryo-protected
in a 30% sucrose solution to prevent formation of ice crystals.
The tissues were snap-frozen in cold isopentane and stored at
−80◦ C. Brains were sliced into 35 µm-thick coronal sections
using a Leica CM1900 cryostat. Sections were serially collected
in a cryoprotectant solution (25% 0.2M PBS, 30% ethylene glycol,
25% glycerol, 20% H2 O) and stored at −80◦ C until use.
c-Fos immunohistochemistry [Experiment 1 (C57BL/6J Rj
mice): vehicle (VEH), n = 7; VORT, n = 7; Experiment 2
(GFAP-TK+ mice): NON-GCV/VEH, n = 8; GCV/VEH, n = 8;
NON-GCV/VORT, n = 8; GCV/VORT, n = 8] was conducted
as previously described (O’Mahony et al., 2010). Sections were
washed 3 × 5 min in 0.01 M PBS (pH 7.4), and incubated in
freshly prepared 0.75% H2 O2 for 20 min to inhibit endogenous
peroxidase. Sections were incubated at room temperature for
20 min in 10% Normal Goat Serum, 0.1% Triton-X 100, in PBS
to prevent non-specific binding. Sections were then incubated
overnight at room temperature with rabbit anti-c-Fos polyclonal
antibody (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA,
United States) in 0.01 M PBS with 1% v/v NGS. Sections were
washed and incubated for 90 min at room temperature with a
secondary biotinylated anti-rabbit antibody (1:100, VECSTAIN
Elite ABC Kit, Vector Laboratories) followed by incubation in
ABC reagent (VECSTAIN Elite ABC Kit, Vector Laboratories).
c-Fos positive cells were detected by incubation with 3, 3diaminobenzidine tetrahydrochloride (DAB: 0.02% w/v; SigmaAldrich, St. Louis, MO, United States) with 0.0075% H2 O2
in PBS. Sections were visualized using an Olympus BX51
microscope; images were captured by an Olympus DP71 digital
camera with Cell F software (Olympus Corporation, Tokyo,
Japan) and c-Fos positive cells were counted. Coordinates of
coronal plates and limits of the structures analyzed were defined
according to a mouse brain atlas [(Paxinos and Franklin, 2001);
the dorsal hippocampus was defined as anterior–posterior (AP)
−0.94 to −2.30 and the ventral hippocampus as AP −2.46 to
−3.80]. For each region, three consecutive sections were analyzed
and an investigator blind to the experimental conditions counted
c-Fos positive cells bilaterally.

RESULTS
Detailed statistical results are provided in
Tables S1–S5.

Effects of Chronic Treatment With VORT
in CD in Adult C57BL/6J Rj Mice
The effects of chronic VORT treatment on CD are shown
in Figure 2 and Supplementary Tables S1, S2. Analysis of
freezing behavior over days in both contexts (A and B for
aversive and non-aversive respectively) revealed a decrease in
freezing behavior in context B in VEH-treated group (Figure 2A)
at day 9 (p = 0.055) and started significantly discriminating
at day 10 (Figure 2A and Supplementary Table S1). VORTtreated mice (Figure 2B) started freezing less in the non-aversive
chamber and started discriminating significantly between the two
contexts at day 6 and until the end of the protocol (Figure 2
and Supplementary Table S1). Finally, discrimination index
analysis revealed that VORT treated mice discriminate faster than
VEH treated mice from day 8 (Figure 2C and Supplementary
Table S2). Overall, this data suggest that VORT improves CD.

R

R

R

Chronic VORT Treatment Improve
Context Discrimination Independently
From Adult Hippocampal Neurogenesis

R

Effects of Ablation of Neurogenesis on CD in Adult
Mice
The consequences of arresting AHN following chronic GCV
treatment in GFAP-TK+ mice were evaluated on CD (Figure 3
and Supplementary Tables S1, S2). Unlike control group (NONGCV/VEH GFAP-TK+ mice) which discriminated at day 9,
GCV/VEH GFAP-TK+ mice started discriminating significantly
between contexts A and B at day 10 (p < 0.05, Figures 3A,B and
Supplementary Table S1). The GCV/VEH GFAP-TK+ group
kept discriminating until the end of the protocol (day 11,
p < 0.01; day 12, p < 0.05; day 13, p < 0.001). If arresting AHN
did not fully impaired CD, it delayed CD performances in adult
mice.

Statistical Analysis

Effects of Vortioxetine Treatment on CD in Mice With
Ablated Neurogenesis

Results are presented as mean ± SEM. Data were analyzed
using unpaired two-tailed student’s ttests or One/Two-way
analysis of variance (ANOVA) repeated measures. Significant
main effects or interactions were followed up with Fisher’s least
significant difference (LSD) post hoc test as appropriate. For
all comparisons, p < 0.05 was the criterion used for statistical
significance. Statistical analyses were performed using GraphPad
Prism 6.0h software (GraphPad Software Inc., La Jolla, CA,

Frontiers in Pharmacology | www.frontiersin.org

Supplementary

Unlike control mice treated with VORT (NON-GCV/VORT
GFAP-TK+ mice) which discriminated at day 6 (p < 0.05) and
from day 9 to the end of the protocol (Figure 3C), GCV/VORT
GFAP-TK+ mice started discriminating from day 9 (p < 0.01)
and kept discriminating until the end of the protocol (Figure 3D
and Supplementary Table S1). It suggests that ablation
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FIGURE 2 | Effects of VORT (1.8 g/kg; ∼10 mg/kg) treatment on CD in C57BL/6J Rj mice. Two-way repeated measures ANOVA of context and day followed by
Fisher’s predicted least-square difference post hoc tests; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001 (A,B: context A versus context B; C: VEH versus
VORT). The n number for CD protocol was: vehicle (VEH), n = 10; Vortioxetine (VORT), n = 10.

of neurogenesis delayed CD performances in adult VORTtreated GFAP-TK+ mice. However, discrimination index analysis
revealed that GCV/VORT GFAP-TK+ mice discriminated
better than GCV/VEH GFAP-TK+ mice (Figure 3E and
Supplementary Table S2; day 9: p < 0.05; day 10: p < 0.05),
indicating that VORT improved CD performances in adult mice.

However, on day 2 of CD protocol, no difference was detected
between the groups (Figure 4B; t = 0.3243 df = 18; p = 0,7495).
Unpaired t-test analysis revealed no difference in freezing
behavior between VEH and VORT group in GFAP-TK+ GCVuntreated mice (Figure 4C; t = 1.419 df = 16, p = 0, 1750) and
GFAP-TK+ GCV-treated mice (Figure 4D; t = 0.4411 df = 13;
p = 0, 6664). However, GCV/VEH GFAP-TK+ mice displayed
a decrease in freezing behavior in aversive context A when
compared to NON-GCV/VEH GFAP-TK+ mice (Figure 4E
and Supplementary Table S3), suggesting that arresting AHN
decreases freezing behavior per se. However, freezing behavior in
VORT-treated mice treated/untreated with GCV was unchanged
(Figure 4F and Supplementary Table S3), suggesting that VORT
treatment reversed the effects of loss of neurogenesis on freezing
activity.

Chronic VORT Treatment Decreased
Freezing Behavior in C57BL/6J Rj and
Reversed the Effects of Arrested AHN on
Freezing Behavior in GFAP-TK+ Mice
The effects of VORT treatment on freezing behavior are shown in
Figure 4. On day 1 of CD protocol, VORT treated mice froze less
than VEH treated mice (Figure 4A; t = 4.072 df = 18; p < 0.001).

Frontiers in Pharmacology | www.frontiersin.org
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FIGURE 3 | Effects of ablation of adult hippocampal neurogenesis on context discrimination in VEH and VORT (1.8 g/kg; ∼10 mg/kg) treated GFAP-TK TG mice.
Two-way repeated measures ANOVA of context and day followed by Fisher’s predicted least-square difference post hoc tests; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001;
∗∗∗∗ p < 0.0001 (A–D: context A versus context B; E: GCV/VEH versus GCV/VORT). The n number for CD protocol was: NON-GCV/VEH, n = 10; GCV/VEH, n = 9;
NON-GCV/VORT, n = 8; GCV/VORT, n = 7. GFAP-TK TG mice, glial fibrillary acidic protein (GFAP)-Thymidine kinase (TK) engineered male; GCV, Ganciclovir; VEH,
vehicle; VORT, Vortioxetine.
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FIGURE 4 | Effects of VORT treatment on freezing behavior in VEH and VORT (1.8 g/kg; ∼10 mg/kg) treated mice. Unpaired two-tailed student’s t-tests between
VEH and VORT group or Two-way repeated measures ANOVA of context and day followed by Fisher’s predicted least-square difference post hoc tests; ∗ p < 0.05;
∗∗ p < 0.01; ∗∗∗ p < 0.001 (A–D: VEH versus VORT; E: VEH versus GCV/VEH; F: VORT versus GCV/VORT). GFAP-TK TG mice, glial fibrillary acidic protein
(GFAP)-Thymidine kinase (TK) engineered male; GCV, Ganciclovir; VEH, vehicle; VORT, Vortioxetine.

In an attempt to understand the molecular mechanisms
underpinning VORT’s effects on CD, shocks-induced c-Fos
activation analysis in the hippocampus in C57BL/6J Rj and
GFAP-TK+ mice were performed.

and statistical analysis is summarized in Supplementary
Table S4. No effects of chronic VORT treatment were
observed in the total ventral hippocampus (Figure 5H)
and neither in the ventral dentate gyrus (DG; Figure 5E),
CA1 (Figure 5F), or CA3 (Figure 5G) areas. VORT
treatment did not alter the number of c-Fos positive cells
in the dorsal CA1 (Figure 5B), dorsal CA3 (Figure 5C)
areas, and in the total dorsal hippocampus (Figure 5D).
Unlike the ventral DG, VORT treatment decreased the
number of c-Fos positive cells in the dorsal DG when

Vortioxetine Effects on Shock-Induced
c-Fos Activation in the Adult
Hippocampus in C57BL/6J Rj Mice
The effects of VORT treatment on shock-induced c-Fos
activation in the hippocampus are shown in Figure 5

Frontiers in Pharmacology | www.frontiersin.org

7

March 2018 | Volume 9 | Article 204

Felice et al.

Vortioxetine Improves Context Discrimination in Mice

FIGURE 5 | Effects of VORT (1.8 g/kg; ∼10 mg/kg) treatment on shock-induced c-Fos activation in the adult hippocampus in C57BL/6J Rj mice (Dorsal
hippocampus, A–D; Ventral hippocampus, E–H). Unpaired two-tailed student’s t-tests between VEH and VORT group; ∗∗ p < 0.01. VEH, vehicle; VORT, Vortioxetine.
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FIGURE 6 | Effects of VORT (1.8 g/kg; ∼10 mg/kg) treatment on shock-induced c-Fos activation in the adult hippocampus (Total DG, A; Dorsal DG, B; Ventral DG,
C) in GFAP-TK TG mice. GFAP-TK TG mice, glial fibrillary acidic protein (GFAP)-Thymidine kinase (TK) engineered male; GCV, Ganciclovir; VEH, vehicle; VORT,
Vortioxetine.

compared to the VEH group (Figure 5A; t = 3.712 df = 12;
p < 0.01).

VORT improved CD in adult mice. VORT-treated mice started
discriminating earlier between the two contexts compared to
control mice (Figure 2C).
It is interesting that VORT treatment is able to improve CD in
C57BL/6J Rj mice, which are characterized by a normal cognitive
profile. Indeed, C57BL/6J Rj mouse strain displays no cognitive
deficits as assessed in different cognitive tasks including a visual
discrimination task and a water maze task when compared
to other mice strains including 129S2/Sv, BALB/c, C3H/He,
CBA/Ca, and DBA/2 mice strains (Brooks et al., 2005). Of note,
VORT-treated mice start discriminating between the safe and
non-safe context before the CD protocol was switched from
randomized to non-randomized in contrast to the control group.
We may have detected lager differences between the two groups
if the protocol was randomized until the end of the experiment.
In line with our finding, acute VORT administration increased
freezing behavior in the retention phase in a contextual fear
condition test suggesting increased contextual memory in
Sprague–Dawley rats (Mork et al., 2013). In addition, other
preclinical findings strongly support a role of VORT in inducing
pro-cognitive effects in rodents (Sanchez et al., 2015). For
example, treatment with VORT improved episodic short-term
memory and spatial memory in rats (novel object recognition,
NOR, and Y-maze spontaneous alterations) respectively (Mork
et al., 2013; du Jardin et al., 2014). Interestingly, VORT restored

Vortioxetine Treatment Did Not Alter the
Number of c-Fos Positive Cells in the
Hippocampus of GFAP-TK Mice
The effects of VORT treatment on stress-induced c-Fos activation
in the hippocampus in GFAP-TK mice are shown in Figure 6 and
statistical values are summarized in Supplementary Table S5.
Two-way ANOVA analysis (treatment and neurogenesis
ablation) revealed that chronic treatment with VORT did not
alter the number of stress-induced c-Fos positive cells in the
whole DG (Figure 6A), dorsal DG (Figure 6B), or ventral DG
(Figure 6C).

DISCUSSION
In this study, we assessed the effects of chronic treatment with
VORT, an antidepressant with multimodal activity, on CD in
adult C57BL/6J Rj mice. Importantly in our study the CD
protocol was randomized for the first 8 days. Thus time was not
an additional cue and mice were not able to predict whether
they would be exposed first to the safe (shock non-associated)
or aversive (shock-associated) context. Chronic treatment with
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earlier than the vehicle group with ablated neurogenesis. In
line with previous observations, VORT treatment improved CD.
Overall, discrimination index analysis revealed that GFAP-TK+
VORT-treated mice discriminated better than the respective VEH
group (Figure 3, day 10: p < 0.05; day 11: p < 0.05). In
addition, chronic treatment with vortioxetine induced a trend
(p = 0.06) for increased total number of doublecortin positive
cells (DCX), a marker of AHN (Wang et al., 2008) in C57BL/6J
Rj mice as observed in recently published study in another
mouse strain (Guilloux et al., 2013) (Supplementary Methods
and Results and Supplementary Figure S1). Overall, our data
indicated that VORT improved CD through neurogenesisindependent mechanism. Importantly, only some behavioral
paradigms in rodents are neurogenesis dependent while others
are neurogenesis independent (Gardier et al., 2009). Indeed, other
brain areas different from the hippocampus are clearly involved
in modulating rodent behavior such as amygdala and cingulate
cortex (Gardier et al., 2009).
Interestingly, VORT-treated mice exhibited significantly lower
freezing levels than VEH mice on the first day of the protocol
following exposure to shock on day 0 (Figure 4). However,
VORT-treated mice displayed similar freezing levels in the
following days of CD protocol. This finding may suggest either
that VORT-treated mice do not recall the shock received on
day 0 or that they are less anxious than VEH treated mice.
Given VORT-treated mice discriminated earlier than VEH
control mice and freezing levels are similar to the VEH group
on the following days, most likely VORT induced anxiolyticlike effects. Accordingly, preclinical findings have shown that
treatment with VORT induced anxiolytic-like effects in mice
(Guilloux et al., 2013) and rats (Mork et al., 2012). Freezing
analysis on day 1 revealed no difference in freezing behavior
between VEH and VORT groups with or without ablation of
neurogenesis in GFAP-TK+ mice. This contradicting finding
may be explained by different genetic makeup. Intriguingly,
freezing behavior analysis revealed that GCV/VEH GFAP-TK+
(ablated neurogenesis) display decreased freezing behavior when
compared to the NON-GCV/VEH GFAP-TK+ group, whereas
mice treated with VORT displayed similar freezing behavior
when neurogenesis is ablated (Figure 4). Thus, VORT treatment
prevented reduction in freezing behavior, i.e., generalization.
In an attempt to further elucidate the mechanisms
underpinning VORT effects on CD we investigated shockinduced c-Fos activation in the hippocampus (Figures 5, 6).
Importantly, recent studies suggest that the hippocampus does
not work as one unit but dorsal and ventral hippocampus
may have different functions. Thus, the dorsal hippocampus
is more involved in mediating cognitive functions, whereas
the ventral hippocampus is more important in the control of
stress responses (Bannerman et al., 1999, 2004). Intriguingly,
VORT decreased c-Fos activation in the dorsal but not ventral
dentate gyrus in the hippocampus. No main effect was observed
in other areas of the hippocampus including CA1, CA3, or
the total hippocampus. Surprisingly, no differences in stressinduced c-Fos activation were observed between groups in the
dorsal and ventral hippocampus in GFAP-TK+ mice. Similar
to the freezing behavior analysis, this may be due to genetic

the memory impairment in NOR and spontaneous alterations
induced by serotonin depletion in rats (Jensen et al., 2014).
Similarly, VORT treatment restored reversal learning impaired
by 5-HT depletion in rats as assessed by the attentional setshifting test, a paradigm that measures cognitive flexibility
(Wallace et al., 2014; Popik and Nikiforuk, 2015). In parallel,
clinical studies supports a role of VORT treatment in cognitive
function (Wallace et al., 2014; Smith et al., 2017) and a recent
study showed that VORT treatment is able to target directly the
neural circuitry implicated in the cognitive deficits in depression
(Smith et al., 2017).
The potential mechanisms underpinning VORT effects on
CD were also investigated. Recent studies suggested a role of
adult neurogenesis in mouse models of PS, namely the ability
to discriminate between similar events. Indeed, increased AHN
is enough to improve separations behavior in mice (Sahay
et al., 2011a). Similarly, ablation of hippocampal neurogenesis
(hippocampal x-ray irradiation) has been shown to impair spatial
PS in adult mice (Clelland et al., 2009). Moreover, another study
showed that AHN is necessary for spatial PS in mouse models
(Tronel et al., 2012). Furthermore, mice with genetic ablation of
neurogenesis were impaired in spatial PS (Tronel et al., 2012).
In addition, AHN may be an adaptive mechanism to optimally
encode contextual or olfactory information (Sahay et al., 2011b).
Unlike control NON GCV/VEH GFAP-TK+ mice
that discriminated from day 9 of the CD protocol
(Figure 3), GCV/VEH GFAP-TK+ mice (ablated neurogenesis)
discriminated from day 10 and keep discriminating until the end
of the protocol. Thus, if arresting AHN with a genetic ablation
strategy did not induce a deficit in CD, it affects negatively the
process. Of note, it is important to highlight that administration
of GCV for 4 weeks to ablate neurogenesis may have induced
compensatory effects or lead to different coping strategies during
the CD test. GCV was administered during CD protocol until
the end of the experiment as described in (Mendez-David et al.,
2017), thus preventing the resume of AHN (Sakalem et al.,
2017). As mentioned above several studies support a role of adult
neurogenesis in rodent models of PS, however other studies do
not find a clear link (Becker, 2016). Recent data suggest that
newly generated neurons are highly active and fire continuously
over time generating increased pattern overlap and exhibiting
less spatial tuning than their mature counterparts (Becker, 2016;
Danielson et al., 2016). However, increased AHN may increase
CD indirectly by increasing feedback inhibition onto mature
granule cells or enhancing pattern integration (Becker, 2016).
Intriguingly, AHN decreases with age whereas PS increases
with age (Yassa and Stark, 2011). Furthermore, while AHN
may play a physiological role in CD, AHN is not required for
the pharmacological effects of some drugs on behavior in mice
(Gardier et al., 2009).
Knowing that chronic VORT treatment increases AHN
(Guilloux et al., 2013), we then investigated whether AHN is
required for VORT improved-CD. Surprisingly, arresting AHN
did not prevent VORT improved-CD. Indeed, GCV/VORT
GFAP-TK+ mice started discriminating on day 9 (p < 0.01)
and kept discriminating until the end of the protocol. Therefore,
GFAP-TK+ mice treated with VORT started discriminating 1 day
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burden for individuals suffering from depression and/or anxiety
disorders.

background differences. Indeed, different mice strain may
display different c-Fos brain activation in response to the same
stress (O’Mahony et al., 2010). Similarly, different rat strains
exhibit a differential expression of c-fos mRNA in response to
restraint stress (Trneckova et al., 2006). Our data highlight a
role of the dorsal dentate gyrus in CD, however the meaning
of decreased c-Fos expression in the dorsal dentate gyrus is
unclear. In agreement with a role of the dorsal hippocampus
in CD, a study showed that ablation of the dorsal but not ventral
hippocampus impairs CD in mice delaying acquisition (Wu and
Hen, 2014). Interestingly, this finding was observed only when
the two contexts were presented to mice not randomly (Wu and
Hen, 2014). In a randomized protocol both dorsal and ventral
hippocampal play a role (Wu and Hen, 2014). Our data may
indicate that although VORT modulates hippocampal neuronal
activity this effect is not necessary to observe the behavioral
effects on CD as observed in GFAP-TK+ mice.
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According to our data, mice with ablated neurogenesis are still
able to acquire the CD protocol and are able to discriminate
between two similar contexts (one safe and one aversive). Thus,
AHN is not necessary to acquire CD. However, mice with
ablated neurogenesis exhibited a slight impairment of learning
the protocol, i.e., 1 day later compared to control mice. This may
suggest that AHN is not necessary but may play a role since the
acquisition of CD protocol is delayed. However, VORT effects
on CD are independent of AHN since no behavioral difference
was observed when neurogenesis was ablated. Furthermore, the
dorsal but not ventral DG may play a role in VORT effects on
CD as revealed by c-Fos analysis in C57BL6 Rj mice. In parallel,
c-Fos analysis in the hippocampus revealed no difference in the
DG and CA1 and CA3 hippocampal areas activation following
an electric shock in mice with ablated neurogenesis and the
respective control group. This data suggest that activation of the
adult hippocampus may not be responsible for the behavioral
phenotype observed in the CD. These data could be expected,
since the role and contribution of the DG and AHN to CD is still
unclear and a matter of debate (Yassa and Stark, 2011).
Overall, the findings further support a role of VORT in
cognition. Future studies should investigate the effects of VORT
treatment on CD in animal models of depression such as chronic
mild stress or social defeat. These models may give more insights
than this study conducted in naïve mice. An ongoing clinical trial
(NCT02969876) investigates the effects of VORT in PS and its
potential mechanisms of action in depressed patients. Further
elucidating the mechanisms underlying VORT effects in CD
could contribute to future strategies for alleviating the disease
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